Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
IL-23 Inhibitor
Advertisement
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Advertisement
